Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5756Lung Neoplasms 3723Small Cell Lung Carcinoma 1021Breast Neoplasms 668Neoplasms 615Colorectal Neoplasms 560Melanoma 479Ovarian Neoplasms 435Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 312Adenocarcinoma of Lung 309Squamous Cell Carcinoma of Head and Neck 306Head and Neck Neoplasms 294Prostatic Neoplasms 285Mesothelioma, Malignant 281Esophageal Neoplasms 266Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 217Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 211Uterine Cervical Neoplasms 209Endometrial Neoplasms 175Sarcoma 171Carcinoma, Hepatocellular 159NSCLC 136Carcinoma 128Kidney Neoplasms 127

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Unresectable Non-small Cell Lung Cancer × Thoracic × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡